Navigation Links
Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients
Date:2/28/2008

SAN DIEGO, Feb. 28 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) today announced that patient dosing has commenced in a Phase I study of ANA773, the company's oral TLR7 agonist prodrug, in patients with advanced solid tumors. This first-in-human trial is a safety and tolerability study designed to identify pharmacologically active doses and preliminary antitumor activity as well as to select the dose and schedule for Phase II trials.

The Phase I trial is a multiple, ascending dose study conducted at several sites in the United States. In addition to safety and tolerability, patients will be monitored for pharmacodynamic responses indicative of immunological stimulation. Initially, patients will be dosed every other day. The company also expects to investigate additional schedules during this first clinical trial and anticipates that up to 60 patients will be enrolled in the study.

"The extensive preclinical investigation Anadys has conducted with ANA773 over the last 18 months has taught us much about the pharmacology of orally administered TLR7 agonists, including the importance of schedule in sculpting the profile of immune activation," said James Freddo, M.D., Anadys' Chief Medical Officer. "We believe ANA773 holds promise for the treatment of a range of malignancies and may have utility when combined with targeted agents, therapeutic antibodies and/or chemotherapy. We are excited about having initiated this first clinical study."

Steve Worland, Ph.D., Anadys' President and Chief Executive Officer, said, "This is an important milestone for Anadys. The initiation of this trial marks the resumption of our clinical investigation of oral TLR7 agonists and moves us closer toward our objective of
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Anadys Pharmaceuticals to Present at the Susquehanna SIGnificant Options in Healthcare Conference
2. Anadys Pharmaceuticals to Report Fourth Quarter and Year-End 2007 Financial Results
3. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
4. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
5. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
6. Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights
7. Anadys Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw Healthcare Conference
8. Anadys Pharmaceuticals to Report Third Quarter 2007 Financial Results
9. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
10. Memory Pharmaceuticals to Announce Fourth Quarter and Full Year 2007 Results on Thursday, March 6, 2008
11. Michael J. Simms Joins Alexza Pharmaceuticals as Senior Vice President, Operations and Manufacturing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014  Bill Jacobs Automotive, a group of car dealerships headquartered ... the Heartland Blood Center and offering free oil change coupons ... place Saturday, Jan. 18 at the Bill Jacobs Cadillac and ... (Photo: http://photos.prnewswire.com/prnh/20140115/MN46637 )  The Bill Jacobs ...
(Date:1/15/2014)... FALLS, N.Y., Jan. 15, 2014   Niagara Thermal ... been selected by Buffalo BioBlower Technologies LLC ("B3") as ... SBIR Phase 2 award from the Army Corps of ... system that kills all biological contaminants and destroys VOCs ...
(Date:1/15/2014)... Village, Calif. (PRWEB) January 15, 2014 ... treatment and management through the genomic analysis of tumor ... offer Therapy Finder™, a web-based cancer decision support application ... reporting option with Cynvenio’s ClearID™ genomic test, Therapy Finder ...
(Date:1/15/2014)... , Jan. 15, 2014 ­ RedBrick Health ... behavior change technology, today announces that EmblemHealth , ... and wellness company, is now providing the RedBrick Compass ... coaching program, to all of its members. EmblemHealth is ...
Breaking Biology Technology:Join the Bill Jacobs Auto blood drive and receive a free oil change 2Niagara Thermal Products LLC Selected as Critical Supplier for Buffalo BioBlower Air Purification Systems 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 2EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 3
... Programs to Include Response Prediction to Ovarian Cancer ... Differentiation of Small Cell From Non-Small Cell Lung Cancer, In Addition, ... Cancer Patients, Which may Serve as the Basis for a Future ... Test ...
... Lead Discovery, COPENHAGEN, June 18 Nuevolution ... drug discovery collaboration with Merck & Co.,Inc., ... to identify novel small molecule leads against several ... uses innovative DNA,labeling to allow fragment-based drug screening ...
... HARTFORD, Conn., June 17 The Connecticut,Technology Council (CTC) ... in,partnership with accounting firm UHY LLP this November, to ... will be,recognized on the basis of revenue growth over ... and minimum revenues of $3 million in,the fourth year., ...
Cached Biology Technology:Rosetta Genomics Announces Three New Diagnostic Tests to Enter Development 2Rosetta Genomics Announces Three New Diagnostic Tests to Enter Development 3Rosetta Genomics Announces Three New Diagnostic Tests to Enter Development 4Rosetta Genomics Announces Three New Diagnostic Tests to Enter Development 5Nuevolution Announces Research and Development Collaboration with Merck & Co. Inc. 2Connecticut Technology Council to Recognize Fast Growing Technology Companies 2
(Date:4/22/2014)... a five-year, $3 million study to determine whether an ... of dissolved organic matter (DOM) through the Connecticut River ... composition and water quality of the watershed and Long ... Foundation,s MacroSystems Biology program, researchers will collect data from ... Canada and runs through five U.S. states, before emptying ...
(Date:4/22/2014)... 2014) Biotechnology scientists must be aware of the ... licensing guidelines, according to a new paper from Rice ... the current issue of the journal Regenerative Medicine ... U.S. Supreme Court ruling in the case Association for ... genes are unpatentable. The court case and rulings garnered ...
(Date:4/22/2014)... Mass. Scientists at the University of Massachusetts Amherst ... Brazil, this week report that they have discovered a ... tributaries of the Negro River in the Amazonia State ... Amherst, with Adlia Nogueira and Jos Antnio Alves-Gomes of ... issue of the journal Proceedings of the Natural ...
Breaking Biology News(10 mins):Connecticut River watershed study will assess impacts of extreme rain events 2Connecticut River watershed study will assess impacts of extreme rain events 3New patenting guidelines are needed for biotechnology 2New patenting guidelines are needed for biotechnology 3New electric fish genus and species discovered in Brazil's Rio Negro 2
... drug has lowered blood sugar levels and inflammation in mice ... be added to the arsenal of drugs used by millions ... The drug consists of a synthetic molecule that stops the ... or MIF. This protein is implicated in a number of ...
... the Australian National University, Research School of Chemistry, has ... Otting is on the editorial board of Springer,s ... Award is granted in recognition of a researcher,s entire ... had a significant impact on their own discipline. The ...
... and the University of Ottawa have identified a promising new ... the leading inherited cause of death in infants and toddlers. ... found that an enzyme called RhoA is overly active in ... can greatly increase survival. The study is published in ...
Cached Biology News:Study points to potential new drug for type 2 diabetes 2Study points to potential new drug for type 2 diabetes 3Study points to potential new drug for type 2 diabetes 4Study opens new avenue for developing treatments for genetic muscle-wasting disease 2
... developed specifically for the stabilization of ... plates/strips. Coating Stabilizer maintains the ... or protein antigen portion of the ... filtered at 0.2 microns., ,Contents: ...
... Novagen's HT96 Isothermal Block is an ... hold HT96 plates and to provide efficient ... plate. This new design of the HT96 ... offers an enhanced product design allowing for ...
Umbilical cord blood neutrophils, For immunohistochemistry (IHC)...
...
Biology Products: